Compare BridgeBio Pharma Inc (BBIO) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs JetBlue Airways Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while JetBlue Airways Corporation trades at $5.81 (market cap $2.13B). The key difference: BridgeBio Pharma Inc is far larger — about 7.8× JetBlue Airways Corporation's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| BBIO | JBLU | |
|---|---|---|
Market Cap | $16.61B | $2.13B |
Sector | Health | Industrials |
52-Week High | $90.17 | $6.46 |
52-Week Low | $47.29 | $4.03 |
Enterprise Value | $18.16B | $9.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
JetBlue (JBLU) trades at $6.07, down 1.94% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a Q2 2026 earnings beat but continues to post net losses, with negative profit margins and declining revenue trends. Recent news includes analyst downgrades from Citigroup citing geopolitical risks, though the company has introduced new fare structures and lounge enhancements to drive growth.
The outlook remains challenging with persistent losses and high debt levels, though cost management and strategic initiatives offer potential upside. Key risks include fuel cost volatility, competitive pressures, and execution of the 2028 profit target. Analyst consensus is cautious with a $5.18 price target below current levels, reflecting skepticism about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
